Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study

Cisplatin plus 5‐fluorouracil is regarded as standard neoadjuvant chemotherapy for esophageal squamous cell carcinoma (ESCC) in Japan, but the prognosis remains poor. We have previously described how definitive chemoradiotherapy with docetaxel, nedaplatin, and 5‐fluorouracil (DNF) led to a very high...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohnuma, Hiroyuki, Sato, Yasushi, Hayasaka, Naotaka, Matsuno, Teppei, Fujita, Chisa, Sato, Masanori, Osuga, Takahiro, Hirakawa, Masahiro, Miyanishi, Koji, Sagawa, Tamotsu, Fujikawa, Koshi, Ohi, Motoh, Okagawa, Yutaka, Tsuji, Yasushi, Hirayama, Michiaki, Ito, Tatsuya, Nobuoka, Takayuki, Takemasa, Ichiro, Kobune, Masayoshi, Kato, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215867/
https://www.ncbi.nlm.nih.gov/pubmed/30137686
http://dx.doi.org/10.1111/cas.13772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215867/
https://www.ncbi.nlm.nih.gov/pubmed/30137686
http://dx.doi.org/10.1111/cas.13772

Ejemplares similares